AlphaCentric Advisors
TRVI icon

AlphaCentric Advisors’s Trevi Therapeutics TRVI Stock Holding History

AlphaCentric Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$363K Buy
25,370
+1,053
+4% +$18.1K 0.32% 97
2026
Q2 		$454K Buy
24,317
+347
+1% +$5.05K 0.38% 95
2026
Q1 		$286K Buy
23,970
+1,303
+6% +$14.6K 0.29% 113
2025
Q4 		$284K Buy
+22,667
New +$262K 0.28% 113

Other funds holding TRVI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Emerald Mutual Fund Advisers Trust
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return
Nan Fung Trinity
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

AlphaCentric Advisors's TRVI Position: Q3 2026 in Review

AlphaCentric Advisors increased its Trevi Therapeutics (TRVI) stake by 4.3% in Q3 2026, buying an estimated $18.1K and bringing the position to 25,370 shares worth $363K. The position accounts for 0.32% of the portfolio, ranked #97.

AlphaCentric Advisors first reported a position in TRVI in Q4 2025 and has held it in 4 quarters since. The position peaked at $454K in Q2 2026. 75 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.

  • AlphaCentric Advisors held 25,370 shares of Trevi Therapeutics worth $363K as of Q3 2026.
  • AlphaCentric Advisors bought 1,053 Trevi Therapeutics shares in Q3 2026, an estimated $18.1K.
  • Trevi Therapeutics made up 0.32% of AlphaCentric Advisors's portfolio in Q3 2026, its #97 holding.
  • AlphaCentric Advisors first reported a position in Trevi Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • AlphaCentric Advisors's Trevi Therapeutics position peaked at $454K in Q2 2026.
  • 75 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.

Based on AlphaCentric Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.